K********g
发帖数: 9389 | |
a****g
发帖数: 8131 | |
K********g
发帖数: 9389 | 3 呵呵呵，不要羡慕加嫉妒哦
【在 a****g 的大作中提到】
: it's ok
|
m*********y
发帖数: 10616 | 4 我只恨
【在 K********g 的大作中提到】
: 呵呵呵，不要羡慕加嫉妒哦
|
y*****l
发帖数: 5997 | 5 Cong!
【在 K********g 的大作中提到】
: 呵呵呵。
|
y*****l
发帖数: 5997 | 6 T-DM1 Significantly Improved Progression-Free Survival in Randomized Phase
II Trial
3 hours 20 minutes ago - BIZ via Comtex
BusinessWireImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today announced that
Roche has disclosed positive top-line results from the first randomized
trial assessing trastuzumab emtansine (T-DM1, previously known as
trastuzumab-DM1) in HER2-positive metastatic breast cancer (MBC). T-DM1
consists of ImmunoGen's DM1 cancer cell-killing agent attached using the
Company's linker to the HER2-targeting antibody, trastuzumab, developed by
Genentech, a member of the Roche Group.
The top-line results disclosed by Roche in a press release today were that
patients treated with T-DM1 had a significant improvement in progression-
free survival compared with patients treated with Herceptin(R) (trastuzumab)
plus chemotherapy (docetaxel) in the Phase II trial comparing these agents
for first-line treatment for HER2-positive MBC.
The detailed findings from this randomized, 137-patient trial are being
submitted for presentation at a future medical conference. Favorable
preliminary data were reported previously from this trial at the 35th
Congress of the European Society of Medical Oncology (ESMO), but progression
-free survival data were not available at that time.(1)
"This top-line information about T-DM1's performance in the first-line
setting is very encouraging and adds to the favorable efficacy and safety
data reported across a number of T-DM1 studies. We look forward to learning
the detailed data when they are reported at a medical conference," said
Daniel Junius, President and CEO.
About Trastuzumab Emtansine (T-DM1)
Trastuzumab emtansine (the generic or International Non-proprietary Name for
T-DM1) utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with
the trastuzumab antibody developed by Genentech. The compound is in global
development by Roche under a collaboration agreement between ImmunoGen and
Genentech.
T-DM1 is in Phase III testing for second-line and first-line treatment of
HER2-positive MBC. A Phase II trial evaluating the safety of T-DM1 in the
neoadjuvant/adjuvant setting began in late 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company'
s expertise in tumor biology, monoclonal antibodies, potent cancer-cell
killing agents and engineered linkers. The Company's TAP technology uses
monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell
killing agents specifically to tumor cells. There are currently seven TAP
compounds in the clinic, with a wealth of clinical data reported with the
technology. ImmunoGen's collaborative partners include Amgen, Bayer Schering
Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group),
Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech. More information about
ImmunoGen can be found at www.immunogen.com.
References
(1)Perez E. et al., ESMO 2010, Abstract LBA3
Herceptin(R) is a registered trademark of Genentech.
This press release includes forward-looking statements. For these statements
, ImmunoGen claims the protection of the safe harbor for forward-looking
statements provided by the Private Securities Litigation Reform Act of 1995.
It should be noted that there are risks and uncertainties related to the
development of novel anticancer products, including trastuzumab emtansine (T
-DM1), including risks related to uncertainties around clinical studies and
data acceptance for presentation, as well as their timings and results. A
review of these risks can be found in ImmunoGen's Annual Report on Form 10-K
for the fiscal year ended June 30, 2010 and other reports filed with the
Securities and Exchange Commission.
SOURCE: ImmunoGen, Inc.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
i**[email protected]
or
For Media:
The Yates Network
Barbara Yates, 781-258-6153 |
K********g
发帖数: 9389 | 7 涨涨涨
【在 K********g 的大作中提到】
: 呵呵呵。
|
R*****8
发帖数: 7056 | 8 555,missed
【在 K********g 的大作中提到】
: 涨涨涨
|
K********g
发帖数: 9389 | 9 我最近买得狗屎运股，可是全部告诉你了哦
不能怪我吧
【在 R*****8 的大作中提到】
: 555,missed
|
R*****8
发帖数: 7056 | 10 追了，跟你喝了唐
你没说为啥买啊，555
运气真好
【在 K********g 的大作中提到】
: 我最近买得狗屎运股，可是全部告诉你了哦
: 不能怪我吧
|
|
|
R*****8
发帖数: 7056 | 11 完了，sold early
师傅，为啥最近bio这么疯狂？
【在 K********g 的大作中提到】
: 我最近买得狗屎运股，可是全部告诉你了哦
: 不能怪我吧
|
y*****l
发帖数: 5997 | 12 +15%
【在 K********g 的大作中提到】
: 涨涨涨
|
a****g
发帖数: 8131 | 13 老牛水平不错啊
不过这种医药股 估计你也没买多少
你笑我酸葡萄吧 |
R*****8
发帖数: 7056 | 14 faint
肠子都青了
老牛请客
【在 a****g 的大作中提到】
: 老牛水平不错啊
: 不过这种医药股 估计你也没买多少
: 你笑我酸葡萄吧
|
u****d
发帖数: 23938 | 15 蛋腚;
【在 K********g 的大作中提到】
: 呵呵呵，不要羡慕加嫉妒哦
|
a****g
发帖数: 8131 | 16
肠子青了是什么说法？
你们娘们就是喜欢夸张
【在 R*****8 的大作中提到】
: faint
: 肠子都青了
: 老牛请客
|
K********g
发帖数: 9389 | 17 我也不知道消息这么快就放出来，我以为要到ASCO呢
【在 R*****8 的大作中提到】
: 追了，跟你喝了唐
: 你没说为啥买啊，555
: 运气真好
|
K********g
发帖数: 9389 | 18 呵呵，我还没卖呢，这个消息其实是重要消息。
【在 R*****8 的大作中提到】
: faint
: 肠子都青了
: 老牛请客
|
R*****8
发帖数: 7056 | 19 你不早说
少卖了1块。crap
【在 K********g 的大作中提到】
: 呵呵，我还没卖呢，这个消息其实是重要消息。
|
K********g
发帖数: 9389 | 20 赫赫，我现在也卖掉了，我也可能卖早了，奶奶的
【在 R*****8 的大作中提到】
: 你不早说
: 少卖了1块。crap
|
|
|
R*****8
发帖数: 7056 | 21 你太牛了，发死啦
【在 K********g 的大作中提到】
: 赫赫，我现在也卖掉了，我也可能卖早了，奶奶的
|
K********g
发帖数: 9389 | 22 我恨我没全仓加马金。
【在 R*****8 的大作中提到】
: 你太牛了，发死啦
|
u****d
发帖数: 23938 | 23 怎么可能全仓,你重仓的YGE又开始锻炼你那颗脆弱的小心脏了...
【在 K********g 的大作中提到】
: 我恨我没全仓加马金。
|
K**********r
发帖数: 2640 | 24 知道你丫就开始得涩。
【在 K********g 的大作中提到】
: 呵呵呵。
|
K********g
发帖数: 9389 | 25 早就习惯了，也不算重仓了。那样我都有一些。
涨跌都不是很怕
【在 u****d 的大作中提到】
: 怎么可能全仓,你重仓的YGE又开始锻炼你那颗脆弱的小心脏了...
|
